News from the FDA/CDC

Developmental disabilities up significantly since 2014


 

The prevalence of children with a developmental disability rose by 21% from 2014 to 2016, according to the National Center for Health Statistics.

In 2016, the prevalence of any diagnosed developmental disability in children aged 3-17 years was 6.99% – a statistically significant increase of 21% over the 5.76% recorded in 2014, the NCHS said in a recent Data Brief.

Autism spectrum disorder was up by a similar amount: 23% from 2014, when prevalence was 2.24%, to 2016, when the prevalence was 2.76% among children aged 3-17 years. Intellectual disability rose in 2015 but dropped in 2016, so the overall increase in prevalence was just 3.6%. The prevalence of other developmental delays, on the other hand, held steady from 2014 to 2015 and then took a big jump, 27.5%, in 2016, the NCHS investigators reported.

Children with diagnosed developmental disability
Combined data from the whole 3-year period show that autism spectrum disorder is almost three times as prevalent in boys (3.63%) as in girls (1.25%), with prevalence among boys also significantly higher for intellectual disability (1.48% vs. 0.9%), other developmental delays (4.77% vs. 2.98%), and any developmental disabilities (8.15% vs. 4.29%), data from the National Health Interview Survey show.

The estimates are based on reports by parents or guardians of ever receiving a diagnosis of each developmental disability from a physician or other medical professional.

Recommended Reading

Austedo approved for treatment of tardive dyskinesia
MDedge Neurology
ADHD meds don’t raise seizure risk in epilepsy patients
MDedge Neurology
Opioid deaths and suicides – twin tragedies that need a community-wide response
MDedge Neurology
VIDEO: Keep index of suspicion high for groups at risk of suicide and substance abuse
MDedge Neurology
VIDEO: Rethinking deep brain stimulation for depression
MDedge Neurology
VIDEO: How to manage surgical pain in opioid addiction treatment
MDedge Neurology
Amyloid imaging changed management for 80% of patients with uncertain dementia diagnosis
MDedge Neurology
Pimavanserin found modestly effective in phase 2 Alzheimer’s psychosis study
MDedge Neurology
Long-term cholinesterase inhibition may slow cognitive decline – and more
MDedge Neurology
Retinal changes may reflect brain changes in preclinical Alzheimer’s
MDedge Neurology

Related Articles